Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer

Journal of Surgical Oncology

Volumn 97, Issue 5, 2008, Pages 445-450

  Sugasawa, Hidekazu ^a   Ichikura, Takashi ^a   Tsujimoto, Hironori ^a   Kinoshita, Manabu ^a   Morita, Daisaku ^a   Ono, Satoshi ^a   Chochi, Kentaro ^a   Tsuda, Hitoshi ^a   Seki, Shuhji ^a   Mochizuki, Hidetaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

CCL5 RANTES; CCR3; CCR5; Chemokine; Chemokine receptor; Gastric cancer

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; RANTES;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; CHEMOKINE CCL5; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CHEMOKINE; STOMACH NEOPLASMS;

EID: 41549105427     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20984     Document Type: Article

References (22)

1. Arenberg DA, Polverini PJ, Kunkel SL, et al.: The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 1997;62:554-562.
2. Kakinuma T, Hwang ST: Chemokines, chemokine receptors, and Cancer metastasis. J Leukoc Biol 2006;79:639-651.
3. Zlotnik A: Chemokines and cancer. Int J Cancer 2006;119:2026-2029.
4. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol 2001;2:108-115.
5. Duell EJ, Casella DP, Burk RD, et al.: Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:726-731.
6. Tsukishiro S, Suzumori N, Nishikawa H, et al.: Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol 2006;102:542-545.
7. Niwa Y, Akamatsu H, Niwa H, et al.: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-289.
8. Kim HK, Song KS, Park YS, et al.: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. Eur J Cancer 2003;39:184-191.
9. Sugasawa H, Ichikura T, Kinoshita M, et al.: Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 2008 (in press).
10. Shinto E, Tsuda H, Ueno H, et al.: Prognostic implication of laminin-5 gamma 2 chain expression in the invasive front of colorectal cancers, disclosed by area-specific four-point tissue microarrays. Lab Invest 2005;85:257-266.
11. Ueda S, Hatsuse K, Tsuda H, et al.: Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 2006;19:788-796.
12. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.
13. Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
14. Mashino K, Sadanaga N, Yamaguchi H, et al.: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 2002;62:2937-2941.
15. Yasumoto K, Koizumi K, Kawashima A, et al.: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 2006;66:2181-2187.
16. Schall TJ, Bacon KB: Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994;6:865-873.
17. Vaday GG, Peehl DM, Kadam PA, et al.: Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006;66:124-134.
18. Johrer K, Zelle-Rieser C, Perathoner A, et ah: Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 2005;11:2459-2465.
19. Wu X, Fan J, Wang X, et al.: Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. Biochem Biophys Res Commun 2007;355:866-871.
20. Robinson SC, Scott KA, Wilson JL, et al.: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63:8360-8365.
21. Slettenaar VI, Wilson JL: The chemokine network: A target in cancer biology? Adv Drug Deliv Rev 2006.
22. Zlotnik A, Yoshie O: Chemokines: A new classification system and their role in immunity. Immunity 2000;12:121-127.